|
|
|
Masimo Corp (NASDAQ: MASI) |
|
|
|
| |
Masimo Corp Outlook |
On February 25 2025 the Masimo Corp provided following guidance
nnMasimo Corporation Reports Q4 and Full-Year 2024 Financial Results with Updated Expectations for 2025nn
IRVINE, California – Masimo (Nasdaq: MASI) has released its financial results for the fourth quarter and the fiscal year that ended on December 28, 2024. Alongside these results, the company has provided revised guidance for the upcoming full year of 2025.
For the fourth quarter of 2024, Masimo reported consolidated revenue of $601 million, marking a 9% increase when evaluated both on a reported basis and a constant currency basis. Within this figure, the company's Healthcare segment generated $368 million in revenue, which corresponds to an 8% growth on a reported basis and a 9% increase when factoring in constant currency adjustments.
Additionally, the report indicates that while details surrounding the specific figures of the 2025 financial guidance have not been disclosed, the company is looking ahead with optimism based on its recent performance and market trends.
This announcement highlights Masimo's commitment to transparency and ongoing communication with its investors and stakeholders as it navigates an evolving financial landscape. As they prepare for 2025, the company aims to leverage its recent successes to drive further growth and enhance shareholder value.,
|
On January 16 2025 the Masimo Corp provided following guidance
nnMasimo Corporation Announces Preliminary Financial Results for Q4 2024 and Guidance for 2025nn
IRVINE, Calif. – Masimo Corporation (Nasdaq: MASI) has released preliminary financial figures for the fourth quarter of 2024 and has also shared insights regarding its expectations for the full year of 2025. The company anticipates that consolidated revenues for the fourth quarter will reach around $601 million, reflecting a notable year-over-year growth of 9% in both reported and constant currency terms.
In addition to the overall revenue figures, Masimo has indicated that healthcare revenue is projected to be approximately $368 million for the same period. This robust growth underscores the company's commitment and performance within the healthcare sector.
While the preliminary results for Q4 2024 provide a positive outlook, Masimo has also set the stage for its financial guidance for the entire year of 2025. Although specific numerical estimates for 2025 have not been fully disclosed in this announcement, the company has hinted at forthcoming details that will elaborate on its financial expectations for the upcoming year.
In summary, Masimo Corporation's preliminary financial results demonstrate solid growth in the fourth quarter of 2024, and the company is poised to share more comprehensive guidance for 2025 in due course.,
|
On July 9 2024 the Masimo Corp provided following guidance
nnMasimo Corp. Announces Preliminary Financial Results and Revenue Estimates for Q2 2024nn
IRVINE, California, July 9, 2024 – Masimo Corporation (Nasdaq: MASI) has released its preliminary financial results for the second quarter, which ended on June 29, 2024. These preliminary results offer insight into the company's performance and set expectations for its financial outcomes.
nnSummary of Preliminary Second Quarter 2024 Financial Results:nn
- nnConsolidated Revenue:nn Masimo anticipates consolidated revenue to be approximately $496 million. This marks a 9% increase on a reported basis and a 10% growth on a constant currency basis.
- nnHealthcare Revenue:nn Specifically, in the healthcare sector, the projected revenue is around $344 million. This represents a significant 22% growth on a reported basis.
The company’s impressive growth indicates robustness and resilience in its financial health, particularly in the healthcare division, which shows substantial year-over-year improvement. These preliminary results reflect Masimo’s continued success in delivering innovative medical solutions and expanding its market presence.
### Financial Guidance
In offering its guidance, Masimo has detailed expectations that underscore strong financial performance for the second quarter of 2024. The anticipated growth rates illustrate the company's ability to navigate market challenges and capitalize on opportunities in both domestic and international markets.
This preliminary announcement sets a positive tone ahead of the full financial disclosure, highlighting Masimo's continued trajectory of growth and its ongoing contribution to healthcare innovation.
For comprehensive and final financial results, stakeholders are encouraged to stay tuned for the company’s full report, which will provide detailed insights and further analysis of the second quarter's performance.
nnAbout Masimo Corporation:nn
Masimo Corporation is a global leader in innovative noninvasive monitoring technologies, delivering solutions that improve patient care, ensure safety, and enhance clinical outcomes. The company is dedicated to advancing healthcare through continuous innovation and strong market strategies.
Stay connected with Masimo for more updates on financial performance and new developments in medical technology.
### Forward-Looking Statements:
This press release contains forward-looking statements based on current expectations, which involve risks and uncertainties. Actual results might differ materially from those projected due to various factors. Masimo disclaims any obligation to update these forward-looking statements unless required by law.
For further inquiries, please contact our investor relations team at [contact details].
---
This extensive rewritten version contextualizes the preliminary financial results within a broader narrative, highlighting key data points and offering a more detailed explanation of Masimo’s anticipated performance for the second quarter of 2024.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
